Cencora, Inc. (NYSE:COR) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Cencora, Inc. (NYSE:COR) have earned a consensus rating of “Moderate Buy” from the thirteen ratings firms that are covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $393.0833.

A number of research firms have recently commented on COR. Robert W. Baird set a $415.00 price objective on shares of Cencora in a research note on Tuesday, January 13th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Cencora in a research report on Monday, December 29th. Wall Street Zen downgraded shares of Cencora from a “buy” rating to a “hold” rating in a research note on Friday, November 28th. Barclays began coverage on shares of Cencora in a research note on Monday, December 8th. They set an “overweight” rating and a $400.00 price objective for the company. Finally, Evercore ISI set a $400.00 target price on Cencora and gave the stock an “outperform” rating in a research report on Thursday, November 6th.

Cencora Stock Up 2.0%

COR stock opened at $359.14 on Friday. The company has a 50 day moving average price of $347.62 and a two-hundred day moving average price of $323.87. The company has a debt-to-equity ratio of 4.32, a quick ratio of 0.55 and a current ratio of 0.90. The stock has a market capitalization of $69.67 billion, a P/E ratio of 45.17, a PEG ratio of 1.68 and a beta of 0.66. Cencora has a one year low of $237.71 and a one year high of $377.54.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.79 by $0.05. The business had revenue of $83.73 billion for the quarter, compared to analysts’ expectations of $83.36 billion. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The business’s revenue was up 5.9% on a year-over-year basis. During the same quarter last year, the firm earned $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, sell-side analysts expect that Cencora will post 15.37 EPS for the current year.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 14th were issued a $0.60 dividend. This is a positive change from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date was Friday, November 14th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s dividend payout ratio (DPR) is 30.19%.

Insider Transactions at Cencora

In related news, EVP Elizabeth S. Campbell sold 3,351 shares of the stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the completion of the sale, the executive vice president owned 23,891 shares of the company’s stock, valued at approximately $8,173,111.10. This represents a 12.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Robert P. Mauch sold 5,096 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the completion of the transaction, the chief executive officer owned 66,726 shares in the company, valued at $23,669,713.98. The trade was a 7.10% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 20,316 shares of company stock worth $7,151,265. 0.38% of the stock is currently owned by company insiders.

Institutional Trading of Cencora

Institutional investors have recently added to or reduced their stakes in the business. Norden Group LLC purchased a new stake in shares of Cencora in the second quarter worth about $222,000. TD Private Client Wealth LLC acquired a new position in Cencora during the 2nd quarter worth approximately $1,663,000. Perigon Wealth Management LLC boosted its holdings in Cencora by 2.8% in the 2nd quarter. Perigon Wealth Management LLC now owns 2,320 shares of the company’s stock worth $696,000 after acquiring an additional 63 shares during the period. Kathmere Capital Management LLC boosted its holdings in Cencora by 42.3% in the 2nd quarter. Kathmere Capital Management LLC now owns 3,265 shares of the company’s stock worth $979,000 after acquiring an additional 970 shares during the period. Finally, Patton Fund Management Inc. acquired a new stake in Cencora in the second quarter valued at approximately $3,378,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.